AI Article Synopsis
- A study tested neutralization effectiveness of clade-specific plasma against primary HIV-1 viruses and pseudoviruses from different strains, using two neutralization platforms.
- In the PBMC assay, the strongest neutralizing antibody responses were observed when the antibody pool matched the virus clade, demonstrating significant cross-recognition in certain clade pairs.
- The pseudovirus assay showed less cross-clade neutralization, but the clade C antibody pool was notably effective, suggesting the need for more research on clade C envelopes to develop broadly neutralizing antibodies.
Article Abstract
A panel of paired primary virus isolates and envelope pseudoviruses from sixty strains representing six HIV-1 clades was tested for neutralization using pooled, clade-specific plasma in two prominently utilized neutralization platforms: a primary isolate assay using peripheral blood mononuclear cells (PBMC) and a pseudovirus assay using a reporter epithelial cell line. Using the PMBC assay, pairing of the antibody pool against homologous clade viruses generated the highest geometric mean neutralizing antibody titer in 4 out of 6 clades tested, and neutralization patterns showed numerous examples of reciprocal cross-recognition between antibody and viruses of specific clade pairs. In the pseudovirus assay, cross-clade neutralization was more limited, with fewer distinct cross-clade relationships evident. The clade C antibody pool was broadly cross-reactive, neutralizing the greatest number of viruses in both assays. These data highlight the importance of the neutralization assay format employed and suggest that clade C envelopes merit further evaluation for the elicitation of broadly neutralizing antibodies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.virol.2008.02.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A novel HIV triple broadly neutralizing antibody (bNAb) combination-based passive immunization of infant rhesus macaques achieves durable protective plasma neutralization levels and mediates anti-viral effector functions.
PLoS One
November 2024
Department of Pediatrics, Weill Cornell Medicine, New York, NY, United States of America.
To eliminate vertical HIV transmission and achieve therapy-free viral suppression among children living with HIV, novel strategies beyond antiretroviral therapy (ART) are necessary. Our group previously identified a triple broadly neutralizing antibody (bNAb) combination comprising of 3BNC117, PGDM1400 and PGT151 that mediates robust in vitro neutralization and non-neutralizing effector functions against a cross-clade panel of simian human immunodeficiency viruses (SHIVs). In this study, we evaluated the safety, pharmacokinetics, and antiviral potency of this bNAb combination in infant rhesus macaques (RMs).
View Article and Find Full Text PDFPotent and broad HIV-1 neutralization in fusion peptide-primed SHIV-infected macaques.
Cell
December 2024
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; Department of Biochemistry and Molecular Biophysics and Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA. Electronic address:
An antibody-based HIV-1 vaccine will require the induction of potent cross-reactive HIV-1-neutralizing responses. To demonstrate feasibility toward this goal, we combined vaccination targeting the fusion-peptide site of vulnerability with infection by simian-human immunodeficiency virus (SHIV). In four macaques with vaccine-induced neutralizing responses, SHIV infection boosted plasma neutralization to 45%-77% breadth (geometric mean 50% inhibitory dilution [ID] ∼100) on a 208-strain panel.
View Article and Find Full Text PDFImmunization of cows with HIV envelope trimers generates broadly neutralizing antibodies to the V2-apex from the ultralong CDRH3 repertoire.
PLoS Pathog
September 2024
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America.
Article Synopsis
- - The study focuses on generating broadly neutralizing antibodies (bnAbs) against HIV's Envelope (Env) by immunizing cows, which show a reliable response compared to common animal models.
- - Two groups of cows were given different regimens of V2-apex focusing immunogens, resulting in some cows producing serum neutralizing antibodies specifically targeting the V2-apex region of Env.
- - The successful isolation of bnAbs from the cows, particularly those with ultralong CDRH3 regions, indicates that these antibodies are more effective in responding to highly glycosylated proteins like HIV Env.
Differences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02_AG.
Virol J
June 2024
U.S. Military HIV Research Program, CIDR, Walter Reed Army Institute of Resarch, Silver Spring, MD, USA.
The magnitude of the HIV-1 epidemic in Nigeria is second only to the subtype C epidemic in South Africa, yet the subtypes prevalent in Nigeria require further characterization. A panel of 50 subtype G and 18 CRF02_AG Nigerian HIV-1 pseudoviruses (PSV) was developed and envelope coreceptor usage, neutralization sensitivity and cross-clade reactivity were characterized. These PSV were neutralized by some antibodies targeting major neutralizing determinants, but potentially important differences were observed in specific sensitivities (eg.
View Article and Find Full Text PDFHuman CD4-binding site antibody elicited by polyvalent DNA prime-protein boost vaccine neutralizes cross-clade tier-2-HIV strains.
Nat Commun
May 2024
Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, 01655, USA.
Article Synopsis
- The study focuses on the challenge of generating tier-2-neutralizing antibodies for HIV vaccines, highlighting the isolation of a specific antibody, HmAb64, from an immunized individual.
- HmAb64 is characterized by its unique genetic structure, derived from germline genes, and was shown to neutralize 10% of the tested HIV-1 pseudo-virus strains.
- The research also reveals the structural details of how HmAb64 binds to the CD4-binding site, proving that a gp120-based vaccine can effectively stimulate the production of antibodies capable of neutralizing tier-2 HIV strains.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!